{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:42:51Z","timestamp":1768250571460,"version":"3.49.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1053\/j.seminoncol.2018.03.005","type":"journal-article","created":{"date-parts":[[2018,3,25]],"date-time":"2018-03-25T23:17:03Z","timestamp":1522019823000},"page":"170-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy"],"prefix":"10.1053","volume":"45","author":[{"given":"Thomas R.","family":"Flint","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James O.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-975X","authenticated-orcid":false,"given":"Miriam","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Janowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2018.03.005_bib1","doi-asserted-by":"crossref","unstructured":"Burotto M, Gormaz JG, Samtani S, et al. Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. Semin Oncol 2018.","DOI":"10.1053\/j.seminoncol.2018.03.003"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.03.005_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1-2","key":"10.1053\/j.seminoncol.2018.03.005_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"issue":"32","key":"10.1053\/j.seminoncol.2018.03.005_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"Van Rooij","year":"2013","journal-title":"J Clin Ocol"},{"issue":"6230","key":"10.1053\/j.seminoncol.2018.03.005_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"NA","year":"2015","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2018.03.005_bib6","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/1811735a0","article-title":"Leucocyte antibodies in sera from pregnant women","volume":"181","author":"Van Rood","year":"1958","journal-title":"Nature"},{"issue":"6391","key":"10.1053\/j.seminoncol.2018.03.005_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0140-6736(46)91925-3","article-title":"In-vivo isosensitisation of red cells in babies with h\u00e6molytic disease","volume":"247","author":"Coombs","year":"1946","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.03.005_bib8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7528","key":"10.1053\/j.seminoncol.2018.03.005_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"6349","key":"10.1053\/j.seminoncol.2018.03.005_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Durham","year":"2017","journal-title":"Science"},{"issue":"21","key":"10.1053\/j.seminoncol.2018.03.005_bib11","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.03.005_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.rbmo.2013.09.016","article-title":"Pregnancy, immunology and evolution","volume":"27","author":"Parham","year":"2013","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.03.005_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni1317","article-title":"Mother\u2019s little helpers: mechanisms of maternal-fetal tolerance","volume":"7","author":"Trowsdale","year":"2006","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ijc.28338","article-title":"Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma","volume":"134","author":"Del Campo","year":"2014","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1053\/j.seminoncol.2018.03.005_bib15","doi-asserted-by":"crossref","first-page":"e26491","DOI":"10.4161\/onci.26491","article-title":"Role of non-classical MHC class I molecules in cancer immunosuppression","volume":"2","author":"Kochan","year":"2013","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.03.005_bib16","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1095\/biolreprod46.6.1176","article-title":"In vivo treatment with interferon-gamma during early pregnancy in mice induces strong expression of major histocompatibility complex class I and II molecules in uterus and decidua but not in extra-embryonic tissues","volume":"46","author":"Mattsson","year":"1992","journal-title":"Biol Reprod"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2567.2008.03019.x","article-title":"Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies","volume":"127","author":"Apps","year":"2009","journal-title":"Immunology"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.03.005_bib18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"45","key":"10.1053\/j.seminoncol.2018.03.005_bib19","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1038\/onc.2008.273","article-title":"HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance","volume":"27","author":"Campoli","year":"2008","journal-title":"Oncogene"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.03.005_bib20","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.4049\/jimmunol.165.12.7017","article-title":"Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors","volume":"165","author":"Magner","year":"2000","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2018.03.005_bib21","doi-asserted-by":"crossref","unstructured":"Pommier A, Anaparthy N, Memos N, et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 2018:eaao4908","DOI":"10.1126\/science.aao4908"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.03.005_bib22","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1172\/JCI28214","article-title":"Constraints in antigen presentation severely restrict T cell recognition of the allogeneic fetus","volume":"117","author":"Erlebacher","year":"2007","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.03.005_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.molmed.2014.12.009","article-title":"Maternal uterine natural killer cells nurture fetal growth: in medio stat virtus","volume":"21","author":"Colucci","year":"2015","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/humrep\/13.1.33","article-title":"Human leukocyte antigen matching and fetal loss: results of a 10 year prospective study","volume":"13","author":"Ober","year":"1998","journal-title":"Hum Reprod"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.03.005_bib25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1073\/pnas.95.3.1178","article-title":"Induction of antigen-specific T cell anergy: an early event in the course of tumor progression","volume":"95","author":"Staveley-O'Carroll","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5236","key":"10.1053\/j.seminoncol.2018.03.005_bib26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.270.5236.630","article-title":"T cell awareness of paternal alloantigens during pregnancy","volume":"270","author":"Tafuri","year":"1995","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood-2002-10-3170","article-title":"Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans","volume":"102","author":"James","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2018.03.005_bib28","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8 + T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"issue":"7","key":"10.1053\/j.seminoncol.2018.03.005_bib29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.03.005_bib30","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.0900408","article-title":"Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression","volume":"183","author":"Liu","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.03.005_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ni1428","article-title":"Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice","volume":"8","author":"Kim","year":"2007","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.chom.2011.06.005","article-title":"Foxp3 + regulatory T cell expansion required for sustaining pregnancy compromises host defense against prenatal bacterial pathogens","volume":"10","author":"Rowe","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.03.005_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1084\/jem.20050019","article-title":"A critical role for the programmed death ligand 1 in fetomaternal tolerance","volume":"202","author":"Guleria","year":"2005","journal-title":"J Exp Med"},{"issue":"5380","key":"10.1053\/j.seminoncol.2018.03.005_bib34","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","article-title":"Prevention of allogeneic fetal rejection by tryptophan catabolism","volume":"281","author":"Munn","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cell.2012.05.031","article-title":"Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict","volume":"150","author":"Samstein","year":"2012","journal-title":"Cell"},{"issue":"19","key":"10.1053\/j.seminoncol.2018.03.005_bib36","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.03.005_bib37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.immuni.2015.08.006","article-title":"Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses","volume":"43","author":"Joshi","year":"2015","journal-title":"Immunity"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.03.005_bib38","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/0008-5472.CAN-06-2925","article-title":"Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses","volume":"67","author":"Hou","year":"2007","journal-title":"Cancer Res"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.03.005_bib39","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1002\/eji.201041093","article-title":"Efficient Treg depletion induces T-cell infiltration and rejection of large tumors","volume":"40","author":"Li","year":"2010","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.03.005_bib40","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","article-title":"Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses","volume":"162","author":"Ho","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.03.005_bib41","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.03.005_bib42","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nri.2017.103","article-title":"Regulation of immunity and inflammation by hypoxia in immunological niches","volume":"17","author":"Taylor","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.03.005_bib43","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0002-9440(10)64849-3","article-title":"Onset of maternal arterial blood flow and placental oxidative stress. A possible factor in human early pregnancy failure","volume":"157","author":"Jauniaux","year":"2000","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.03.005_bib44","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1084\/jem.20170356","article-title":"A nonimmune function of T cells in promoting lung tumor progression","volume":"214","author":"Green","year":"2017","journal-title":"J Exp Med"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.03.005_bib45","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cell.2013.10.054","article-title":"A special population of regulatory T cells potentiates muscle repair","volume":"155","author":"Burzyn","year":"2013","journal-title":"Cell"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.03.005_bib46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cell.2017.05.002","article-title":"Regulatory T cells in skin facilitate epithelial stem cell differentiation","volume":"169","author":"N","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.03.005_bib47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.molmed.2017.03.001","article-title":"Connecting the metabolic and immune responses to cancer","volume":"23","author":"Flint","year":"2017","journal-title":"Trends Mol Med"},{"issue":"6230","key":"10.1053\/j.seminoncol.2018.03.005_bib48","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"issue":"50","key":"10.1053\/j.seminoncol.2018.03.005_bib49","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma- associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1053\/j.seminoncol.2018.03.005_bib50","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.03.005_bib51","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.03.005_bib52","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1053\/j.seminoncol.2018.03.005_bib53","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat Med"},{"issue":"7193","key":"10.1053\/j.seminoncol.2018.03.005_bib54","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nature06868","article-title":"Vascular normalization in Rgs5-deficient tumours promotes immune destruction","volume":"453","author":"Hamzah","year":"2008","journal-title":"Nature"},{"issue":"11","key":"10.1053\/j.seminoncol.2018.03.005_bib55","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2018.03.005_bib56","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"8","key":"10.1053\/j.seminoncol.2018.03.005_bib57","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.03.005_bib58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"issue":"7681","key":"10.1053\/j.seminoncol.2018.03.005_bib59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"issue":"7528","key":"10.1053\/j.seminoncol.2018.03.005_bib60","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1053\/j.seminoncol.2018.03.005_bib61","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.03.005_bib62","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.03.005_bib63","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2016.08.011","article-title":"Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade","volume":"30","author":"H","year":"2016","journal-title":"Cancer Cell"},{"issue":"6086","key":"10.1053\/j.seminoncol.2018.03.005_bib64","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1220030","article-title":"Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface","volume":"336","author":"Nancy","year":"2012","journal-title":"Science"},{"issue":"22","key":"10.1053\/j.seminoncol.2018.03.005_bib65","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1158\/0008-5472.CAN-11-1466","article-title":"Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control","volume":"71","author":"Hong","year":"2011","journal-title":"Cancer Res"},{"issue":"23","key":"10.1053\/j.seminoncol.2018.03.005_bib66","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra1213566","article-title":"Pregnancy and infection","volume":"370","author":"Kourtis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.03.005_bib67","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1136\/ard.2005.037580","article-title":"Benefit of pregnancy in inflammatory arthritis","volume":"64","author":"Straub","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.03.005_bib68","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.rdc.2007.01.002","article-title":"Lupus activity in pregnancy","volume":"33","author":"Clowse","year":"2007","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.03.005_bib69","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s10875-011-9627-2","article-title":"Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study","volume":"32","author":"Kraus","year":"2012","journal-title":"J Clin Immunol"},{"issue":"15","key":"10.1053\/j.seminoncol.2018.03.005_bib70","doi-asserted-by":"crossref","first-page":"eaan2946","DOI":"10.1126\/sciimmunol.aan2946","article-title":"An immune clock of human pregnancy","volume":"2","author":"Aghaeepour","year":"2017","journal-title":"Sci Immunol"},{"issue":"40","key":"10.1053\/j.seminoncol.2018.03.005_bib71","doi-asserted-by":"crossref","first-page":"14506","DOI":"10.1073\/pnas.1416569111","article-title":"Enhanced natural killer-cell and T-cell responses to influenza A virus during pregnancy","volume":"111","author":"Kay","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1053\/j.seminoncol.2018.03.005_bib72","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/annonc\/mdx181","article-title":"Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes","volume":"28","author":"Connell","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2018.03.005_bib73","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s002620050620","article-title":"Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients","volume":"48","author":"Goto","year":"1999","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.03.005_bib74","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1634\/theoncologist.2017-0226","article-title":"Cancer immunotherapy trials underutilize immune response monitoring","volume":"23","author":"Connell","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib76","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-immunol-032712-100003","article-title":"Immunology of the maternal-fetal interface","volume":"31","author":"Erlebacher","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10.1053\/j.seminoncol.2018.03.005_bib77","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib78","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","article-title":"Innate immune recognition of cancer","volume":"33","author":"Woo","year":"2015","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.03.005_bib79","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ni.3800","article-title":"Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells","volume":"18","author":"Gao","year":"2017","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.03.005_bib80","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/ni.3809","article-title":"SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-\u03b2 signaling","volume":"18","author":"Cortez","year":"2017","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1053\/j.seminoncol.2018.03.005_bib81","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.4049\/jimmunol.1500689","article-title":"Composition, development, and function of uterine innate lymphoid cells","volume":"195","author":"Doisne","year":"2015","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2018.03.005_bib82","unstructured":"A study of an anti-KIR antibody lirilumab in combination with an anti-PD1 antibody nivolumab and nivolumab plus an anti-CTLA-4 ipilimumab antibody in patients with advanced solid tumors. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01714739."},{"key":"10.1053\/j.seminoncol.2018.03.005_bib83","unstructured":"Study of IPH2201 (monalizumab) and cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02643550."},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib84","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"10110","key":"10.1053\/j.seminoncol.2018.03.005_bib85","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/S0140-6736(17)32894-5","article-title":"Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia","volume":"390","author":"Ghorani","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1053\/j.seminoncol.2018.03.005_bib86","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nri.2017.38","article-title":"Immunological implications of pregnancy-induced microchimerism","volume":"17","author":"Kinder","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminoncol.2018.03.005_bib87","unstructured":"YERVOY (ipilimumab) injection - FDA. 2015;1-32. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125377s073lbl.pdf."},{"key":"10.1053\/j.seminoncol.2018.03.005_bib88","unstructured":"OPDIVO (nivolumab) injection, for intravenous use Label - FDA. 2016:1-58. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125554s022lbl.pdf."},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clim.2012.08.006","article-title":"The developing human preterm neonatal immune system: A case for more research in this area","volume":"145","author":"Sharma","year":"2012","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.03.005_bib90","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.03.005_bib91","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.03.005_bib92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ctrv.2009.11.007","article-title":"Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors","volume":"36","author":"Azim","year":"2010","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.03.005_bib93","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive and Acquired Resistance to Cancer Immunotherapy","volume":"155","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2018.03.005_bib94","unstructured":"Parham P. The immune system. Ed 3. Taylor & Francis Group, New York: Garland Science. 2009."}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775418300678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775418300678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T08:10:25Z","timestamp":1570954225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775418300678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0093775418300678"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.03.005","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}